Volume 5, Issue 3
Perspectivep. 295
Human papillomavirus screening and vaccines for cancer prevention: what is on the horizon?
Author(s): Cornelia L Trimble, Patti Gravitt and Richard BS Roden
Appendicesp. 380
Author Guidelines: Volume 5 Issue 3
Appendicesp. 379
Acknowledgment: Volume 5 Issue 3
Appendicesp. 377
Indices: Volume 5 Issue 3
Appendicesp. 376
Glossary: Volume 5 Issue 3
Review Articlep. 339
Therapeutic human papillomavirus vaccination
Author(s): Andreas M Kaufmann and Achim Schneider
Review Articlep. 325
Efficacy of a prophylactic human papillomavirus vaccine against high-grade vulval and vaginal intraepithelial neoplasia
Author(s): Jorma Paavonen
Review Articlep. 313
Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials
Author(s): Diane M Harper
Perspectivep. 305
Evaluating the potential benefits of universal worldwide human papillomavirus vaccination
Author(s): F Xavier Bosch, Silvia de Sanjosé and Xavier Castellsagué
Forewordp. 261
Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention
Author(s): Eduardo L Franco and Jorma Paavonen
Review Articlep. 367
What is the clinical utility of interferon-�± release assays for the diagnosis of TB in high-TB-burden countries?
Author(s): Peter Daley and Poorvi Chordia
Drug Evaluationp. 355
Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction
Author(s): Andrew Myatt and Ian Eardley
Appendicesp. 351
Bulletin Board: Volume 5 Issue 3
Special Reportp. 289
Sound implementation of human papillomavirus vaccination as a community-randomized trial
Author(s): M Lehtinen, KM French , J Dillner, J Paavonen & G Garnett
Research Highlightsp. 283
Highlights from the latest articles in human papillomavirus vaccination and cervical cancer research
Author(s): Rachel Skinner & Julia Brotherton
Interviewp. 279
Dr Kevin Ault speaks to Charlotte Barker, Commissioning Editor
News and Viewsp. 273
HPV and cervical cancer
Editorialp. 269
The need for actions to effectively prevent cervical cancer: priorities and future directions of EUROGIN
Author(s): Joseph Monsonego
Editorialp. 265
Cross-protection from human papillomavirus 16/18 against types 45 and 31: fact or fancy?
Author(s): Karen J Nishida , J Matthew Pearson and Leo B Twiggs
